CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a natural defense system in bacteria that scientists have adapted into a powerful gene-editing tool. This ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...